Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood

By LabMedica International staff writers
Posted on 04 Mar 2026

Alzheimer’s disease begins developing years before memory loss or other symptoms become visible. More...

Misfolded proteins gradually accumulate in the brain, disrupting normal cellular processes. Current diagnostic blood tests primarily measure the levels of certain proteins, but these markers may not fully capture early molecular changes associated with disease progression. Researchers have now developed a blood test that detects Alzheimer’s disease by analyzing the physical shapes of proteins circulating in the bloodstream.

In a collaborative study led by researchers at The Scripps Research Institute (La Jolla, CA, USA), the team used a chemical tagging technique combined with mass spectrometry to examine how proteins fold and interact in blood plasma samples. This method identifies which portions of a protein are exposed or hidden within its three-dimensional structure. When proteins misfold—a hallmark of neurodegenerative diseases—these structural features shift. By tracking these changes, researchers created a detailed molecular profile associated with different stages of cognitive decline.

The researchers analyzed blood samples from 520 volunteers, including healthy individuals, patients with mild cognitive impairment, and those diagnosed with Alzheimer’s disease. Using machine learning models, the team identified structural patterns in three proteins—C1QA, CLUS, and ApoB—that were strongly associated with disease progression. The deep learning model distinguished healthy aging, mild cognitive impairment, and Alzheimer’s disease with an accuracy of 83.44%. The structural approach also outperformed traditional models that measure only protein quantities. In a smaller follow-up group of 50 participants, the model correctly tracked disease progression 86% of the time.

The findings, published in Nature Aging, suggest that structural protein signatures may provide earlier and more detailed insight into Alzheimer’s disease than existing blood-based tests. Researchers also observed links between protein structure changes, genetic risk factors such as apolipoprotein E variants, and differences in neuropsychiatric symptoms between men and women. Further studies involving larger patient populations and longer follow-up periods will be needed to validate the test. If confirmed, this structural biomarker approach could help clinicians detect Alzheimer’s earlier, monitor disease progression, and evaluate responses to emerging therapies.

“With this work, we established a potential new biomarker panel that reveals structural disruptions in proteins linked to Alzheimer’s disease that are invisible to traditional approaches,” said John R. Yates III, a professor of Integrative Structural and Computational Biology at The Scripps Research Institute. “This approach accurately distinguishes stages of the disease, meaning that it could help enable earlier diagnosis.”

Related Links:
The Scripps Research Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Portable POCT Blood Gas Analyzer
BD100
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.